[Ulcerative colitis. Chronic active course].
Dignass
A U
AU
Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charité, Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin.
Herrlinger
K
K
Schölmerich
J
J
D000284:Administration, Oral; D000328:Adult; D000367:Age Factors; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001379:Azathioprine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002908:Chronic Disease; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000627:therapeutic use; D003082:Colectomy; D003093:Colitis, Ulcerative / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery / Q000628:therapy; D018849:Controlled Clinical Trials as Topic; D003920:Diabetes Mellitus; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage / Q000627:therapeutic use; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D009747:Nutritional Physiological Phenomena; D011247:Pregnancy; D012008:Recurrence; D012074:Remission Induction; D012307:Risk Factors; D013997:Time Factors
D000890:Anti-Infective Agents; D007166:Immunosuppressive Agents; D002939:Ciprofloxacin; D015122:Mercaptopurine; D001379:Azathioprine; D008727:Methotrexate
Chronisch aktiver Verlauf.